Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Orpha-Devel Handels und Vertriebs GmbH, Wintergasse 85/1B, A-3002, Purkersdorf, Austria
Pharmacotherapeutic group: Drugs used in alcohol dependence
ATC code: N07BB04
Naltrexone hydrochloride is an orally used, long acting specific opioid antagonist. Naltrexone hydrochloride binds competitively to receptors which are located in the central and peripheral nervous system and hence blocks the access for exogenously administered opioids.
Treatment with Adepend 50 mg film-coated tablets does not lead to physical or psychological dependence. No tolerance for the opioid antagonising effect is seen.
The mechanism of action of naltrexone hydrochloride is not completely elucidated. An interaction with the endogenous opioid system is assumed. Alcohol consumption in humans has been hypothesised to reinforce an alcohol-induced stimulation of the endogenous opioid system.
A therapy with Adepend 50 mg film-coated tablets is a non-aversive therapy and does not cause reactions when alcohol is ingested. Therefore there are also no disulfiram-like reactions.
The main effect of the treatment with Adepend 50 mg film-coated tablets seems to be a reduction of the risk of a full relapse after having consumed a limited amount of alcohol. This gives the patient the possibility to escape a full relapse with complete loss of control because of decreased stimulation.
Naltrexone hydrochloride reduces the desire for alcohol (“craving”) during abstinence and after alcohol ingestion. The reduction of desire for alcohol lowers the risk of a full relapse of abstinent and non-abstinent patients.
After oral administration naltrexone hydrochloride is rapidly and completely absorbed from the gastrointestinal tract. Peak plasma concentration is reached within one hour.
Plasmaprotein-binding is 21%. The steady-state plasma-level is 8.55 mg/ml.
Metabolism takes place mainly by a first-pass effect in the liver. Naltrexone hydrochloride is basically hydroxylated to the main active metabolite 6-beta-naltrexol and, to a lesser extent, to 2-hydroxy-3-methoxy-6-beta-naltrexol.
The substance is excreted primarily renally. About 60% of the perorally given dose is excreted within 48 hours as glucuronidised 6-beta-naltrexol and naltrexone hydrochloride.The plasma-half-life of naltrexone hydrochloride is approximately 4 hours. The plasma-half-life of 6-beta-naltrexol is 13 hours.
Five to ten times higher plasma concentrations of naltrexone hydrochloride have been reported in cirrhotic patients.
Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. However, there is some evidence on hepatotoxicity with increasing dose. Reversible increases of liver enzymes have been found in patients treated with therapeutic or higher doses (see section 4.4 and 4.8).
Naltrexone hydrochloride (100 mg/kg/day, approximately 140 times the human therapeutic dose) caused a significant increase of pseudo-pregnancy in rats. A decrease of the pregnancy rate of mated female rats also occurred. The relevance of these observations to human fertility is not known.
Naltrexone hydrochloride has been shown to have an embryotoxic effect in rat and rabbit when given in doses approximately 140 times the human therapeutic dose. This effect was demonstrated in rats dosed with 100 mg/kg/day naltrexone hydrochloride prior to and throughout gestation, and rabbits treated with 60 mg/kg/day naltrexone hydrochloride during the period of organogenesis.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
